Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840173 | 1.00 | NOS2 (0.50) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL30052597 | 0.89 | NOS2 (0.42) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL146828 | 0.87 | NOS2 (0.46) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL995604 | 0.87 | NOS2 (0.46) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL6859669 | 0.87 | NOS2 (0.46) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL9737609 | 0.83 | NOS2 (0.43) | NOS2NOS3NOS1GLI1DPP4 | |
| Phthalic Acid SCHEMBL6322396 | 0.83 | ELANE (0.44) | NOS2NOS3NOS1DPP4DPP8 | |
| Phthalic Acid SCHEMBL5424564 | 0.83 | ELANE (0.44) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL31298402 | 0.82 | NOS2 (0.42) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL28288006 | 0.82 | NOS2 (0.42) | NOS2NOS3NOS1GLI1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120575190-A | Method for synthesizing proline carbamate by catalyzing guanidine-based porous organic polymer | 广西师范大学 | 2025-09-02 | — | — | CN | disclosed |
| CN-120575190-A | Method for synthesizing proline carbamate by catalyzing guanidine-based porous organic polymer | 广西师范大学 | 2025-09-02 | — | — | CN | disclosed |
| CN-104818276-B | Single-stranded nucleic acid molecules for controlling gene expression | 株式会社博纳克 | 2020-12-11 | — | — | CN | disclosed |
| EP-2933333-B1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORP (JP) | 2018-02-21 | — | — | EP | disclosed |
| CN-104059911-B | single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | 株式会社博纳克 | 2017-01-04 | — | — | CN | disclosed |
| CN-104004018-B | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | 株式会社博纳克 | 2017-01-04 | — | — | CN | disclosed |
| CN-103052711-B | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | 株式会社博纳克 | 2016-08-03 | — | — | CN | disclosed |
| US-20160108400-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | ORION CORPORATION (FI) | 2006-10-12 | — | — | US | disclosed |
| EP-1581489-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2005-10-05 | — | — | EP | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| US-20040241743-A1 | Methods for the diagnosis and treatment of bone disorders | TCP INNOVATIONS LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| WO-2004060862-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2004-07-22 | — | — | WO | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| EP-1384074-A2 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | Metabometrix Limited (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002086502-A2 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | METABOMETRIX LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | PREP, DNPEP, IDE | NOS2 1612/4885NOS3 829/4885NOS1 1040/4885 |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | NOS2 845/4885NOS3 937/4885NOS1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.